Newsbenzinga
Pfizer, Astellas Expand PADCEV-Keytruda Label With FDA Nod In Bladder Cancer
· Published
Article summary
FDA approves Pfizer and Astellas' PADCEV plus Keytruda for muscle-invasive bladder cancer, backed by Phase 3 survival data.
An excerpt from the original article.
Comments —
Loading comments…